Generic Medicine Info
Pre-existing drug-induced or radiation therapy-induced bone marrow suppression. Pregnancy and lactation. Concomitant administration with live vaccines.
Special Precautions
Renal and hepatic impairment. Monitoring Parameters Monitor LFT, kidney function prior to and during treatment. Monitor CBC with differential frequently during induction and for 2-3 weeks after, electrolytes prior to each dose, bone marrow studies periodically; ECG during and after administration. Monitor for signs and symptoms of infection, tumour lysis syndrome, bleeding, and fluid status during therapy. Monitor infusion site during infusion.
Adverse Reactions
Significant: Bone marrow suppression, cardiovascular effects (e.g. acute arrhythmia, heart failure, bradycardia, tachycardia), extravasation, tumour lysis syndrome. Blood and lymphatic system disorders: Thrombocytopenia, pancytopenia. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain. General disorders and administration site conditions: Pyrexia, infusion site phlebitis; injection site irritation, necrosis, skin inflammation. Hepatobiliary disorders: Hepatitis, jaundice, hepatic insufficiency. Investigations: Increased hepatic enzymes. Metabolism and nutrition disorders: Hypokalaemia. Nervous system disorders: Grand mal seizure, headache, hypoesthesia, dizziness, peripheral neuropathy Psychiatric disorders: Affect lability. Renal and urinary disorders: Hematuria. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Purpura, alopecia, urticaria, rash. Vascular disorders: Hypotension.
Potentially Fatal: Infection, haemorrhage, stomatitis.
Drug Interactions
May increase risk of cardiotoxicity with diuretics or nephrotoxic drugs (e.g. aminoglycosides). May diminish therapeutic effects of vaccines. May potentiate adverse effects with other cytotoxic agents.
ATC Classification
L01XX01 - amsacrine ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on amsacrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in